Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Desmoid Tumor

In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Desmoid Tumor

Samip R. Master et al.
Free Books & Documents

Excerpt

Desmoid tumors are mesenchymal neoplasms that are considered locally invasive but nonmetastasizing. They are also known as aggressive fibromatosis, deep fibromatosis, and musculoaponeurotic fibromatosis. Even though they do not metastasize, they are locally invasive and cause significant morbidity and mortality. There is no standard approach to treating desmoid tumors; managing them is challenging and requires discussion at a multidisciplinary tumor board.

Despite surgical resection, desmoid tumors have a high rate of local recurrence; accordingly, they have been labeled as intermediate locally aggressive tumors by the World Health Organization (WHO). According to WHO, desmoid tumor is a "clonal fibroblastic proliferation that arises in the deep soft tissues and is characterized by infiltrative growth and a tendency toward local recurrence but an inability to metastasize," even though it may be multifocal in the same limb or body part. Systemic treatment is used in patients where surgery and radiation therapy are either not feasible or will not achieve a cure. Recently, several new drugs have been licensed by the United States Food and Drug Administration (FDA) to treat patients with DT.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Samip Master declares no relevant financial relationships with ineligible companies.

Disclosure: Ankit Mangla declares no relevant financial relationships with ineligible companies.

Disclosure: Chintan Shah declares no relevant financial relationships with ineligible companies.

References

    1. PDQ Pediatric Treatment Editorial Board. PDQ Cancer Information Summaries [Internet] National Cancer Institute (US); Bethesda (MD): 2024. Dec 17, Childhood Soft Tissue Sarcoma Treatment (PDQ®): Health Professional Version. - PubMed
    1. Wang Z, Wu J, Lv A, Tian X, Hao C. En bloc resection for intra-abdominal/retroperitoneal desmoid-type fibromatosis with adjacent organ involvement: A case series and literature review. Biosci Trends. 2018;12(6):620-626. - PubMed
    1. Cassidy MR, Lefkowitz RA, Long N, Qin LX, Kirane A, Sbaity E, Hameed M, Coit DG, Brennan MF, Singer S, Crago AM. Association of MRI T2 Signal Intensity With Desmoid Tumor Progression During Active Observation: A Retrospective Cohort Study. Ann Surg. 2020 Apr;271(4):748-755. - PMC - PubMed
    1. Ganeshan D, Amini B, Nikolaidis P, Assing M, Vikram R. Current Update on Desmoid Fibromatosis. J Comput Assist Tomogr. 2019 Jan-Feb;43(1):29-38. - PMC - PubMed
    1. Timbergen MJM, van de Poll-Franse LV, Grünhagen DJ, van der Graaf WT, Sleijfer S, Verhoef C, Husson O. Identification and assessment of health-related quality of life issues in patients with sporadic desmoid-type fibromatosis: a literature review and focus group study. Qual Life Res. 2018 Dec;27(12):3097-3111. - PMC - PubMed

Publication types

LinkOut - more resources